Page last updated: 2024-10-19

phosphorylcholine and ER-Negative PR-Negative HER2-Negative Breast Cancer

phosphorylcholine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies

Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.

Research Excerpts

ExcerptRelevanceReference
"Triple negative breast cancers express receptors for gonadotropin-releasing hormone (GnRH) in more than 50% of the cases, which can be targeted with peptidic analogs of GnRH, such as triptorelin."1.42Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). ( Buchholz, S; Engel, JB; Kwok, CW; Ortmann, O; Seitz, S; Treeck, O, 2015)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Song, Z1
Tu, X1
Zhou, Q1
Huang, J1
Chen, Y1
Liu, J1
Lee, S1
Kim, W1
Nowsheen, S1
Luo, K1
Yuan, J1
Lou, Z1
Kwok, CW1
Treeck, O1
Buchholz, S1
Seitz, S1
Ortmann, O1
Engel, JB1

Other Studies

2 other studies available for phosphorylcholine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
A novel UCHL
    Cell death & disease, 2019, 05-21, Volume: 10, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Cell Line, Tumor; Female; Humans; Mice; Mi

2019
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
    Targeted oncology, 2015, Volume: 10, Issue:3

    Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

2015